A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of TRIA-662 (A Hypolipidemic Agent) in Healthy Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs N-1-methylnicotinamide (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Cortria Corporation
- 03 Sep 2013 New trial record